WeVote
Log In

Bill

Bill

S 7435

Authorizes pharmacists to dispense HIV pre-exposure and post-exposure prophylaxis

2025 Regular Session Introduced by Brad Hoylman-Sigal and 2 co-sponsors

Authorizes pharmacists to dispense HIV PrEP and PEP, expanding access through pharmacies and reducing barriers for people at risk of HIV.

REFERRED TO HIGHER EDUCATION
0
WeVote Research Nonpartisan
Bill Summary · S 7435

Summary of Senate Bill S 7435 — Authorizes pharmacists to dispense HIV pre-exposure and post-exposure prophylaxis

Overview

Senate Bill S 7435 would authorize pharmacists to dispense HIV pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP). The measure is currently in the referral stage, having been referred to the Higher Education committee on April 16, 2025.

Purpose and Intent

  • Expand access to HIV prevention by allowing pharmacists to provide PrEP and PEP directly.
  • Leverage the accessibility of pharmacies to reduce barriers to obtaining HIV prevention medications, potentially reaching individuals who have limited access to primary care or specialty clinics.

Key Provisions (as indicated by the bill’s title)

  • Authority for pharmacists to dispense PrEP and PEP.
  • The bill would establish the framework under which pharmacists may dispense these medications, with the full statutory language detailing requirements, qualifications, and procedures.
  • Likely considerations include patient screening, counseling, documentation, follow-up, and coordination with prescribers and other healthcare providers.
  • The legislation would operate within existing state pharmacy and healthcare regulations and would be complemented by any necessary regulatory actions by relevant agencies (e.g., health department or board of pharmacy).

Note: The precise operational details (eligibility criteria, required training, consent, labeling, refill protocols, reporting, and cost/insurance considerations) will be specified in the bill’s text and any implementing regulations.

Who would be Affected

  • Pharmacists and pharmacies: would gain new authority and responsibilities to dispense PrEP/PEP.
  • Patients seeking PrEP/PEP: would have expanded, potentially more convenient access through community pharmacies.
  • Healthcare providers and systems: may need to coordinate with pharmacists for prescription information, monitoring, and referrals.
  • Insurers and payors: implications for coverage of pharmacist-dispensed PrEP/PEP; details would depend on subsequent regulations and payer policies.

Legislative Status and Timeline

  • Introduced: April 16, 2025.
  • Action: Referred to Higher Education (Senate Committee). Referred twice on the same date in the version notes, indicating committee referral in different contexts or readings.
  • Next steps: Await committee consideration, potential amendments, and eventually floor votes in the Senate, with companion actions in the Assembly (as indicated by related companion bills).

Related Legislation

  • Related/Senate and Assembly counterparts from prior sessions:
    • S 7704 (prior-session)
    • S 728 (prior-session)
    • S 3297 (prior-session)
    • A 9013 (prior-session)
    • A 358 (companion)
  • These references suggest ongoing interest in expanding pharmacist authority for HIV prevention across sessions.

Potential Impacts and Considerations

  • Public Health: Potentially increased PrEP/PEP uptake and reduced HIV transmission rates due to greater access.
  • Access and Equity: Improved access for rural or underserved communities and individuals without regular primary care.
  • Safety and Quality: Need for clear guidelines on patient assessment, counseling, and coordination with prescribers to ensure appropriate use and monitoring.
  • Implementation: Requires regulatory alignment, pharmacist training, and possibly changes to payer policies and reimbursement structures.
  • Fiscal and Administrative: The bill would likely undergo fiscal analysis to assess costs to the state and payers, as well as the administrative burden on pharmacies.

If you’d like, I can tailor this summary to a specific audience (policymakers, advocates, healthcare providers) or compare S 7435 with its related bills for a fuller context.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.